Skip to main content
    D

    Denali Therapeutics Inc (DNLI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $18.00
    -0.08 (-0.44%)

    Market Cap: $2.90B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Denali Therapeutics Inc (DNLI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Denali Therapeutics (DNLI) has a market cap of $2.90B and an enterprise value of $2.80B. It kept -1470.50% of revenue as net income over the last 12 months. Its share count is up 9.26% from a year earlier.

    Total Valuation

    Enterprise value is 3.55% below the market cap, as cash exceeds debt.

    Market Cap$2.90B
    Enterprise Value$2.80B
    Latest price (Nov 17, 2026)$18.00

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.57% in the quarter ended Sep 30, 2026 and grew 5.44% a year over 2 years.

    Shares Outstanding188.39M
    Shares Change (YoY)+9.26%
    Shares Change (QoQ)+0.57%
    Share Count Growth (2Y CAGR)+5.44%

    Valuation Ratios

    Sales and book value multiples are 158.6x and 3.7x. Its year-end P/S ranged from 3.3x to 111.4x from 2017 to 2023.

    P/S Ratio158.6x
    Forward P/S53.8x
    P/B Ratio3.7x
    P/TBV Ratio3.8x

    Valuation history and multiples

    Price Statistics

    The stock is up 3.21% over 52 weeks and trades 8.21% below its 50-day average.

    Beta (1Y)1.51
    52-Week Change+3.21%
    1-Month Change-0.22%
    3-Month Change-29.93%
    6-Month Change-0.61%
    5-Year Change-60.83%
    Total Return (1Y)+3.21%
    Total Return (3Y CAGR)-1.37%
    Total Return (5Y CAGR)-17.50%
    Return vs SPY (1Y)-8.58%
    Max Drawdown (1Y)-35.28%
    Max Drawdown (3Y)-63.68%
    Sharpe Ratio (1Y)0.05
    Correlation with SPY (1Y)0.38
    50-Day Average$19.61
    200-Day Average$21.18
    52-Week Range$15.34 to $27.30
    RSI (14 Days)38.7
    Average Volume (20 Days)1.49M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.21x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.21x
    Quick Ratio5.94x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -33.94% over the last 12 months, against a 5-year average of -32.10%.

    Return on Equity (ROE)-33.94%
    Return on Assets (ROA)-25.03%
    ROE (5Y Average)-32.10%
    ROA (5Y Average)-26.23%
    ROIC (5Y Average)-54.78%
    Asset Turnover0.02x
    Inventory Turnover0.02x
    Receivables Turnover1.87x
    Cash Conversion Cycle3337 days

    Scores

    DNLI has an Altman Z-Score of 3.28, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score3.28
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $21.38M over the last 12 months.

    Revenue$21.38M
    Gross Profit$18.23M
    Operating Income-$532.01M
    Pretax Income-$314.32M
    Net Income-$314.42M
    Reported EPS (TTM)-$2.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 73.52% of the $1.26B in total assets.

    Cash and Equivalents$102.87M
    Total Debt$0
    Net Cash$102.87M
    Net Cash Per Share$0.55
    Working Capital$496.45M
    Shareholder Equity$926.39M
    Book Value Per Share$4.92
    Tangible Book Value$891.89M
    Tangible Book Per Share$4.73
    Total Assets$1.26B
    Total Liabilities$329.65M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $5.80M of capital spending, operating cash flow left -$449.99M of free cash flow.

    Operating Cash Flow-$444.19M
    Capital Expenditures$5.80M
    Free Cash Flow-$449.99M
    FCF Per Share-$2.82
    Depreciation and Amortization$16.52M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2488.14%.

    Gross Margin85.26%
    Operating Margin-2488.14%
    Pretax Margin-1470.03%
    Net Margin-1470.50%
    FCF Margin-2104.54%

    Growth

    Book Value Per Share Growth (2Y CAGR)-11.98%
    Tangible Book Per Share Growth (2Y CAGR)-11.98%

    Revenue and profit by year

    Dividends and Yields

    DNLI does not pay a dividend. Its free cash flow yield is -13.27%.

    FCF Yield-13.27%
    Buyback Yield-6.76%
    Shareholder Yield-6.76%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About DNLI

    What is DNLI's market cap?

    Denali Therapeutics has a market cap of $2.90B. Its enterprise value, which adds debt and subtracts cash, is $2.80B.

    How many shares of DNLI are outstanding?

    Denali Therapeutics has 188.39M shares outstanding. The count is up 9.26% from a year earlier.

    Does DNLI pay a dividend?

    No. Denali Therapeutics does not pay a dividend.

    How much debt does DNLI have?

    Denali Therapeutics has $0 of total debt and $102.87M of cash and equivalents, a net cash position of $102.87M.